Group 1 - Pfizer Inc. is considered one of the best inexpensive stocks to buy currently, particularly following a licensing agreement with Novavax for the Matrix-M adjuvant technology [1] - The Matrix-M technology is intended to enhance immune responses to vaccines and will be utilized by Pfizer for two infectious diseases, with Pfizer managing development, manufacturing, and commercialization [1] - Pfizer announced positive results from the BREAKWATER trial, showing a 64% objective response rate for the BRAFTOVI regimen combined with cetuximab and FOLFIRI in patients with metastatic colorectal cancer, compared to 39% for standard treatment [2][3] Group 2 - The addition of chemotherapy to the BRAFTOVI regimen significantly improved response rates, indicating potential flexibility in treatment options for patients with BRAF V600E mutations [3] - Pfizer's operations encompass the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products both in the US and internationally [4]